University of Arizona Cancer Center director David S. Alberts, MD, is among this year’s Lifetime Achievement honorees at the 2012 AZBio Awards for Achievement, to be held Oct. 23 at the Phoenix Convention Center.
Dr. Alberts, along with Raymond L. Woosley, MD, of the Arizona Center for Education and Research on Theraputics, will receive Lifetime Achievement Awards, commemorating each man’s contributions to the medical field.
"Arizona is the land of the pioneers," said Joan Koerber-Walker, president and CEO of the Arizona Bioindustry Association. "This year, as we celebrate 100 years of statehood, AZBio is shining the spotlight on two pioneers who exemplify Arizona’s pioneer spirit and led in the creation of new discoveries and built up institutions that will pioneer new innovations for decades to come."
In addition to his duties as UACC director, Dr. Alberts is currently regents professor of medicine, pharmacology, nutritional science, and public health at the University of Arizona College of Medicine.
During his career, Dr. Alberts has served as an advisor to numerous cancer research foundations and committees, such as Chair of the Oncologic Drug Advisory Committee to the FDA (1984-1986), and was a member of the NCI’s Board of Counselors (to the Division of Cancer Prevention, 1990-1994), the Board of Scientific Advisors (1999-2006), and on the coordinating subcommittee to the Clinical Translational Advisory Committee, NCI (2006-2009).
Dr. Alberts’ primary focus is translational cancer prevention and treatment research. The emphasis of his laboratory-based and clinical research has been on the chemoprevention and treatment of such pervasive and potentially deadly diseases as cancers of the breast, colon, ovary, and skin.
Under Dr. Alberts’ leadership, the extensive research portfolio of the University of Arizona Cancer Center includes more than $60 million in annual research funding, including four large NCI interdisciplinary programs, and two Special Programs of Research Excellence — one in gastrointestinal cancers and one in lymphoma.
Clinically, Dr. Alberts pioneered new treatments for advanced ovarian cancers, including in vitro tumor cell chemosensitivity testing for personalized medicine strategies, intraperitoneal chemotherapy, and maintenance chemotherapy. Presently, Dr. Alberts helps to coordinate Phase I and II and pharmacokinetic drug studies at the University of Arizona Cancer Center for molecularly-targeted chemopreventive agents.
His laboratory research is concentrated on the evaluation of new surrogate endpoint biomarkers for cancer prevention trials with a special focus on precursor lesions for bladder, breast, colon, cervical, endometrial, ovarian, prostate, and skin cancers, using quantitative histopathology (i.e. karyometric) approaches. His NCI-funded drug and diagnostics research has resulted in more than two-dozen patents and the co-founding of five Arizona pharmaceutical and biotechnology companies.
Dr. Alberts has authored or co-authored more than 550 peer reviewed publications, more than 100 book chapters and 60 invited articles, and has served as editor and co-editor of eight books.
In June 2001, he was acknowledged by Science to be one of the top three National Institutes of Health-funded clinical researchers in the United States. In 2003, the American Association for Cancer Research (AACR) recognized his contributions to clinical care in the field of cancer with the Joseph H. Burchenal Clinical Research Award, and in 2004, the American Society for Preventive Oncology gave him its Distinguished Career Award for research excellence.
Also in 2004, the AACR awarded Dr. Alberts with its AACR-Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research Worldwide.
Dr. Alberts received his MD in 1966 from University of Virginia School of Medicine. He conducted his internship at the University of Wisconsin, before becoming a clinical associate in medical oncology at the National Cancer Institute’s Baltimore Cancer Research Center. Dr. Alberts conducted his internal medicine residency at the University of Minnesota and then served on the faculty of the University of California, San Francisco, for five years and obtained Board certification in Medicine and Medical Oncology in 1973. He joined the University of Arizona College of Medicine in 1975 as an Assistant Professor, where he has served for nearly 37 years.
-Sept. 4, 2012